Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Non-Regulatory

MPI participates at Biotech Showcase in San Francisco

Regulatory

MPI and Mundipharma EDO GmbH enters agreement of DRP(TM) for their anti cancer lead compound EDO-S101 in clinical trials

Regulatory

MPI og Mundipharma EDO GmbH indgår aftale om brug af MPI’s DRP(TM) biomarkør til deres førende lægemiddelkandidat EDO-S101 til behandling af kræft i kliniske forsøg

Regulatory

MPI unblinds prospective study of LungChip prognosticator in early lung cancer

Regulatory

MPI afblinder prospektivt studie af LungChip prognosticator i tidlig lungekræft

Regulatory

DRP(TM) enables Irofulven clinical trial in prostate cancer

Non-Regulatory

New academic drug screening platform for cancer treatment

Regulatory

Presentation of use of DRP(TM) in Top1 at AACR congress in Boston

Non-Regulatory

MPI – announces 3 abstracts on the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston

Regulatory

Medical Prognosis Institute A/S – Interim Report First Half 2015

Regulatory

MPI will publish its half-year report for the first half year of 2015 on August 31st

Non-Regulatory

MPI’s spinout, Oncology Venture announces first day of trading at the Swedish stock exchange AktieTorget

Regulatory

MPI’s spinout, Oncology Venture announces oversubscription of 370 % of its emission prior to listing at the AktieTorget

Regulatory

MPI’s spin-out, Oncology Venture annoncerer overtegning på 370% i forbindelse med aktieemission før IPO på AktieTorget

Regulatory

Oncology Venture Sweden AB, a spinout from MPI announces its IPO at the Swedish AktieTorget

Regulatory

Medical Prognosis Institute and Nemucore Announce Strategic Partnership

Regulatory

MPI og Nemucore indgår strategisk partnerskab om klinisk udvikling af et ny kræftlægemiddel med anvendelse MPI’s DRP(TM) Biomarkør

Regulatory

MPI’s spin-out Oncology Venture og Lantern Pharma annoncerer partnerskab med henblik på at udvikle Irofulven til metastatisk prostatakræft

Regulatory

MPI’s drug development arm Oncology Venture and Lantern Pharma announce partnership to advance Irofulven for metastatic prostate cancer

Regulatory

Oncology Venture, MPI’s drug development arm raises more than 6 million DKK from private investors